Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial
Primary result · TIR (70-180 mg/dL)Result — go to the resultMean difference 15.0 percentage pointsAuthors' conclusion
Closed-loop therapy improved glycemic control more than did CSII + CGM in people with type 2 diabetes.
Study context
- Population
- People with T2D previously treated with CSII; mean age 63 (SD 9) years, 35% women, mean HbA1c 7.9% (SD 0.9)crossover
- Participants
- 17 people
- Comparison
- Hybrid closed-loop vs CSII + continuous glucose monitoring (CGM)
- Primary endpoint
- Percentage TIR (70-180 mg/dL)
Methodological detailscrossover, two-period, open-label, multicenter, Conducted August 2022 to July 2023
- Crossover
- Two-period
- Open-label
- Multicenter
- Conducted August 2022 to July 2023
Primary result
TIR (70-180 mg/dL)
Mean difference
15.0 percentage points
P < 0.001
By group
As reported in the abstract
Secondary outcomes
Other CGM metrics and insulin dose
- Decrease in TAR, GMI and glucose variability, and increase in daily insulin dose
Sleep (actimetry)
- Improvement in sleep fragmentation during closed-loop treatment
Original publication
Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial. Diabetes Care. Published 6 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →